Elevate Now is a healthtech startup based in New Delhi, India, that offers doctor-led, subscription-based medically supervised weight loss programmes for consumers.

This Startup Deep Dive explains what Elevate Now does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Elevate Now in Brief

• What it is: Elevate Now is an Indian Medical weight loss company based in New Delhi (reports differ: some 2026 coverage gives Bengaluru).
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• It runs a fully online, doctor-led, root-cause clinical weight loss platform with subscription programmes of 3 to 24 months.
• Each user is assigned a physician trained in obesity medicine plus a dedicated health coach.
• It diagnoses drivers such as insulin resistance, inflammation and hormonal imbalances using blood diagnostics and continuous glucose monitoring data.
• Funding: About Rs 18 crore (about $2M) seed plus an earlier pre-seed (reported about $2M); a database lists $1.99M+ across 2 rounds (reports differ).

Elevate Now Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Elevate Now?

Elevate Now operates in the Medical weight loss space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Elevate Now.

• It runs a fully online, doctor-led, root-cause clinical weight loss platform with subscription programmes of 3 to 24 months.
• Each user is assigned a physician trained in obesity medicine plus a dedicated health coach.
• It diagnoses drivers such as insulin resistance, inflammation and hormonal imbalances using blood diagnostics and continuous glucose monitoring data.
• Where clinically appropriate, doctors prescribe supervised GLP-1 or related obesity-medicine therapies.
• It also offers a non-surgical gastric balloon option and plans to expand into nutraceuticals, GLP-1 support products and doctor training (company-stated).

The Origin Story of Elevate Now

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Rahul Maroli, Suryansh Kumar.
• Founded in 2022; most profiles credit Rahul Maroli, who is described on the company side as CEO and founder with earlier leadership and P&L roles at Ola and Zee5.
• Other sources name Suryansh Kumar as founder or co-founder, so founder attribution differs across sources.
• Early 2023 coverage described a doctor-led, medication-based model with health and habit coaching and a co-branded obesity clinic in Aurangabad, before the model shifted to mostly online.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Medical weight loss sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2022: company founded.
• March 2023: pre-seed round led by W Health Ventures, with Narayana Health and Swiggy co-founder Sriharsha Majety (reported).
• 2023: opened a co-branded obesity clinic in Aurangabad (reported).
• FY25: revenue about Rs 4.2 crore, up about 300.9% from about Rs 1.0 crore in FY24 (reported).
• February 2026: Rs 18 crore seed led by Physis Capital.
• By early 2026: over 30,000 paying users onboarded (company-stated); some profiles claim 50,000+ enrolled.

Elevate Now Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Pre-seed, March 2023, about $2M (reported), led by W Health Ventures with Narayana Health and Sriharsha Majety.
• Seed, February 2026, Rs 18 crore (about $2M), led by Physis Capital with Inflection Point Ventures and Titan Capital.

How Does Elevate Now Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Fully online subscription programmes of 3 to 24 months with physician supervision and health coaching.
• Revenue comes from programme fees; medicines are prescribed by doctors where clinically appropriate.
• Plans to add supplements (nutraceuticals), GLP-1 support products and doctor training programmes (company-stated).

The Numbers: Elevate Now Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY25 revenue about Rs 4.2 crore, up about 300.9% from about Rs 1.0 crore in FY24 (reported).
• Average month-on-month revenue growth of 17% between April 2025 and January 2026 (company-reported).
• Company-reported outcomes: average weight loss of about 10 kg over six months; 90% weight maintenance six months after the weight loss phase.

Market Opportunity for Elevate Now

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Described as India's first medical weight loss company (company-stated).
• Rising interest in GLP-1 obesity therapies in India is pulling digital players into medically assisted weight loss.

Technology and Product at Elevate Now

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Blood diagnostics and continuous glucose monitoring data feed personalised plans.
• The seed money is earmarked for the technology platform, clinical research, supplements and personalisation systems; AI is being added for clinical and operational work (company-stated).

Team and Culture at Elevate Now

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Rahul Maroli is described as CEO and founder; Suryansh Kumar is named as co-founder or founder in other sources.
• Employee counts conflict across profiles (44 vs 391), so headcount is unreliable.

Elevate Now Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Elevate Now

• Sources conflict on founder, headquarters and funding totals, so company claims should be treated cautiously.
• Company-stated targets (Rs 400 crore ARR this year, Rs 1,000 crore next) are far above reported FY25 revenue of about Rs 4.2 crore.
• Dependence on GLP-1 and prescription obesity drugs exposes it to regulatory, pricing and safety scrutiny.
• Crowded field of well-funded digital health and international GLP-1 clinic players.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Elevate Now Growth Outlook: What to Watch

• Plans to use the seed money on its platform, clinical research, supplements and personalisation (company-stated).
• Targets Rs 400 crore ARR by the end of the year and Rs 1,000 crore the year after (company-stated).
• Intends to expand into nutraceuticals, GLP-1 support products and doctor training.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Elevate Now can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Elevate Now Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Elevate Now

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Elevate Now.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Elevate Now

Studying a company in the Medical weight loss space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Elevate Now.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Elevate Now as a Startup

• Customer clarity: Can Elevate Now name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Elevate Now is part of India’s growing Medical weight loss ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Elevate Now FAQs: Frequently Asked Questions

What is Elevate Now?

Elevate Now is a healthtech startup based in New Delhi, India, that offers doctor-led, subscription-based medically supervised weight loss programmes for consumers. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Elevate Now?

Elevate Now was founded by Rahul Maroli, Suryansh Kumar, and the company reports a founding year of 2022.

How much funding has Elevate Now raised?

About Rs 18 crore (about $2M) seed plus an earlier pre-seed (reported about $2M); a database lists $1.99M+ across 2 rounds (reports differ). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Elevate Now make money?

Elevate Now earns revenue from its Medical weight loss products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Elevate Now?

Reported rivals include Healthify (HealthifyRx), Juniper, Endocare, Calibrate. See the competitor comparison above for how they differ.

What are the main risks for Elevate Now?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Payswiff — Payswiff: Chola bought 72% of the payments firm for INR 450 Cr | Innovaccer — Innovaccer: Noida-rooted healthtech valued near $3.4B. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.